

**How to Cite:**

Deivasigamani, A., Gangasani, N. R., Muniyasamy, M., Boopathy, U., & Chandrasekar, S. (2022). Preliminary verification of *Bacopa monniera* and network pharmacology research for the treatment of non-alcoholic fatty liver disease. *International Journal of Health Sciences*, 6(S2). <https://doi.org/10.53730/ijhs.v6nS2.6831>

## **Preliminary verification of *Bacopa monniera* and network pharmacology research for the treatment of non-alcoholic fatty liver disease**

**Arivukodi Deivasigamani**

Research Scholar, Department of Biochemistry, School of Life Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117

**Narasimha Reddy Gangasani**

Research Scholar, Department of Biochemistry, School of Life Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117

**Muneeswari Muniyasamy**

Research Scholar, Department of Biochemistry, School of Life Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117

**Usharani Boopathy**

Assistant Professor, Department of Biochemistry, School of Life Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117

**Shobana Chandrasekar**

Assistant Professor, Department of Biochemistry, School of Life Sciences, Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai – 600117

Corresponding author email: [shobana.sls@velsuniv.ac.in](mailto:shobana.sls@velsuniv.ac.in)

**Abstract**---Bacoside - A, a dynamic component of *Bacopa monniera* is utilized in different ailments. The pharmacodynamics and cellular pathways overseeing the impacts of Bacoside- A on NAFLD stay unclear. In this study, we examined Bacoside - A pharmacology through evaluation of its chemical constituents and assessed and screened its components using drug likeness, pharmacokinetic characteristics (absorption, distribution, metabolism, excretion, and toxicity), and appropriate compensation mechanisms. We performed expectations of the dynamic BM fixings based on invert pharmacophore matching and compared different NAFLD-related

genes to decide potential BM targets. Atomic docking experiments of the dynamic components were performed to uncover cellular targets. Explanation examination of both target qualities and related pathways were evaluated through the DAVID database. Cytoscape computer program was utilized to build a “component-target- path” network for the treatment of NAFLD by BM. Through data analysis, 9 active BM substances and 10 targets related to NAFLD encompassing 4 cellular pathways were identified. Data were verified through enzyme-linked immunosorbent assay and Western blot analysis. These findings provide new references for the network pharmacology of Ayurvedic medicinal compounds and NAFLD treatment.

**Keywords**---network pharmacology, NAFLD, pharmacodynamic substance base, action mechanism, verification experiment.

## Introduction

Non-alcoholic fatty liver disease (NAFLD) is the fundamental wellspring of ambitious liver torment. NAFLD joins two fanatically superb prognostic ailments: nonalcoholic smooth liver contamination and non-alcoholic steatohepatitis (NASH); the last covers a wide level of torment validity, including fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (European Association, 2016). The constructions pulled in with the new turn of events and movement of NAFLD may be a prompt delayed consequence of metabolic characteristics talked concerning innate lack and are related with higher energy insistence. Metabolic confusion (MS) is an improvement of metabolic changes related with a long possibility making cardiovascular and diabetes (Abenavoli et al., 2016). Patients with NAFLD have various components of MS and are after a short time considered to be the liver piece of MS (Xu et al., 2015, Sattar et al., 2014). The definite instrument of how NAFLD creates has not been completely explained. Nonetheless, a lop-sidedness between the union or flood of hepatic lipids furthermore, their oxidation or fare, which is presumably brought about by metabolic disorder like diabetes and corpulence, may assume a significant part in the improvement of NAFLD (Kwon et al., 2012, Kopee et al., 2011). Epidemiological investigations gauge that around 25% of grown-ups in the United States have NAFLD (Diehl et al., 2017, Sayiner et al., 2016, Bhala et al., 2013) furthermore, that NAFLD happens even more regularly in individuals with corpulence (70%) or diabetes (50.1%) (Sattar et al., 2014, Kwon et al., 2012). Also, basic greasy liver illness forms into constant non-alcoholic steatohepatitis (NASH) in roughly 20% of influenced patients (Henao et al., 2012, Matteoni et al., 1999). NASH-related fibrosis forms into cirrhosis in 40–62% of patients following 5–7 years of follow up (Hui et al., 2003, Adams et al., 2005, Starley et al., 2010) and a further 4–27% of NASH cases form into hepatocellular carcinoma (HCC) (Ratziu et al., 2002). NAFLD is a significant overall clinical issue with restricted treatment alternatives. Right now, the fundamental way to deal with NAFLD the executives is weight reduction through way of life changes, like expanded actual activities and dietary changes. All things considered, accomplishing and keeping up weight reduction objectives are trying for patients. Hence, coupling pharmacologic treatment of NASH with way of life alterations is frequently essential (Le et al., 2012). Regardless of the various tried

drug alternatives, none of them address the issues of treatment for NAFLD (Corrado et al., 2014, Beaton, 2012). Common mixtures from spices and food, in any case, have been found to be successful for easing of NAFLD.

The *Bacopa monnieri* (Scrophulariaceae) entire plant establishes the notable medication brahmi. It is astringent, purgative, carminative, stomach related, depurative, cardiogenic, diuretic, bronchodilatory, emmenagogue, febrifuge and tonic. It is additionally known to have mitigating, anticonvulsant and antiulcer properties. It is utilized in the native arrangement of medication for the treatment of asthma, raspiness, craziness, epilepsy and as a powerful nerve tonic (Warrier et al., 1994; The Wealth of India, 1988). The medication shapes a significant element of various Ayurvedic arrangements like Brahmighritam, Brahmirasayanam. The juice of leaves is given to kids for help in bronchitis and loose bowels. The glue of leaves is utilized as solution for stiffness (The Wealth of India, 1988).

The plant *Bacopa monnieri* has been represented to contain steroidal and triterpenoidal saponins as huge constituents close by alkaloids (brahmin, herpestine, nicotine), sterols ( $\beta$  sitosterol, stigmasterol and stigmasterol esters), triterpenes (betulic corrosive and betulinic corrosive), greasy hydrocarbons (dotriacontane, triacontane, heptacosane, nonacosane and hentriacontane) glycosides (phenyl glycosides, mannitol) and aminoacids (aspartic corrosive, alphaalanine, glutamic corrosive and serine) as minor constituents (Rastogi and Mehrotra, 1995; Rastogi and Mehrotra, 1991; Rastogi and Mehrotra, 1993). The steroidal saponins, Bacoside An and Bacoside B are optical isomers and Bacoside B might be an antique framing during the disconnection of Bacoside A. The other bacosides are Bacoside A1 and Bacoside A3 (Rastogi and Mehrotra, 1998). The other bacosides have been viewed as dammarane type triterpenoid saponins known as bacopasaponin A-G and bacopasides I-V. The bacopasaponins A-G and bacosides I-V, contain either jujubogenin or pseudojujubogenin as aglycone part and L-arabinopyranosyl, D-glucopyranosyl as glycone moieties (Chakravarty et al., 2001; Mahato et al., 2000; Garai et al., 1996a; Garai et al., 1996b; Chakravarty et al., 2003). The triterpenoids point by point from this plant *Bacopa monnieri* are bacogenin A1, bacogenin A2 (an isomer of A1), bacogenin A3 and bacogenin A4 (embelin lactone) and known betulic appalling and betulinic harming (Rastogi and Mehrotra, 1993). The normalized methanolic concentrate of this plant containing 38% of Bacoside A was accounted for to show antiulcerogenic action when regulated at the dosages of 10-50 mg kg<sup>-1</sup> b.w. twice day by day for 5 days in various gastric ulcer models (Sairam et al., 2001). Our past examinations show the neuroprotective impact of Bacoside-An on 6-hydroxy dopamine instigated Parkinson's illness in rodents through conduct, biochemical and immunohistochemical contemplates (Shobana and Sumathi, 2013).

Notwithstanding this information, the dynamic fixings of BM utilized in NAFLD treatment stay muddled and the major cell targets administering its movement remain vague. To address this, this examination utilized organization pharmacology investigation, visual organization programming, existing information bases, and "multialgorithm-multicomponent-multitarget" coordinated examination, to contemplate the dynamic segments of BM also, its mechanism(s) of activity during NAFLD treatment.

## Materials and Methods

This study surveyed the compound creation of BM through writing information bases, drug similarity (DL), and retention, appropriation, digestion, discharge, and poisonousness (ADMET) evaluations, to foresee both pharmacology and toxicology. The distinguished mixtures went through turn around pharmacophore coordinating to get likely targets. NAFLD-related qualities were evaluated in Malacard and GeneCard data sets and contrasted with BM focuses with get possible instruments of activity for BM during NAFLD treatment. Utilizing Autodock programming, BM dynamic fixings were docked with expected focuses in the opposite atom, and the objectives of dynamic BM constituents during NAFLD treatment were anticipated. Quality targets were examined utilizing the DAVID data set, and related BM pathways for NAFLD were anticipated. The "segment target-way" network for BM treatment of NAFLD was built utilizing Cytoscape programming. We finished organization pharmacological examinations on the parts and components of BM movement during NAFLD treatment. The boundaries were as per the following.

### Acquisition of Chemical Constituents

The chemical composition of BM was inferred from literature and traditional Ayurvedic medicine systems pharmacology databases, and specific structural formulas were identified in Pubchem and Chempider. When a specific structural formula was not identified, original papers were sourced. Structures were incorporated utilizing ChemBioDraw 14.0 programming and documents were kept up with in the mol2 design.

### Screening of Chemical Constituents

The acquired compound parts were consecutively exposed to DL and ADMET screening. The DL screening instrument was given by the molsoft and SymMap site, and the mol design document was inputted into DL expectations. The dynamic elements of BM were screened at a DL  $\geq 0.18$  as a source of perspective for drug-like screening. We imported compound records got from DL screening into PreADMET and performed ADME and poisonousness forecasts. For ADME, we chose Caco-2 porousness (Caco2), oral bioavailability (OB), and plasma protein restricting (PPB) as pointers, and set the edges as Caco2  $\geq 0.4$ , OB  $\geq 30\%$ , and PPB  $\geq 20\%$ . For harmfulness expectations, Ames Carcino Mouse, and hERG hindrance tests were chosen as markers adding up to 10 focuses. The Ames test comprised 4 points, the Carcino Mouse test accounted for 3 points, and hERG inhibition tests accounted for 3 points. Scores  $\geq 6$  were selected. A total of 52 compounds were finally screened. Scoring criteria are shown in Table 1.

Table 1. Scoring Criteria and Toxicity Predictions.

Score	Ames test	Carcino mouse	hERG inhibition
Full	Negative	Negative	Low risk
2	-	-	Medium risk
1	Positive	Positive	High risk

Detailed information on 52 phytochemicals from *B. monnieri* was collected from the literature and other web sources. A list of biologically phytomolecules is depicted in Table 2.

Table 2. List of Phyto molecules

S.No	Compounds	Abbreviations/Acronyms
1.	Nicotine	Nt
2.	D-Mannitol	D-Mn
3.	Bacoside A	BCS A
4.	Bacopasaponin A	BCSN A
5.	Bacopasaponin B	BCSN B
6.	Bacopasaponin C	BCSN C
7.	Bacopasaponin D	BCSN D
8.	Bacopasaponin E	BCSN E
9.	Bacopasaponin F	BCSN F
10.	Bacopasaponin G	BCSN G
11.	Bacopaside I	BPS I
12.	Bacopaside II	BPS II
13.	Bacopaside III	BPS III
14.	Bacopaside IV	BPS IV
15.	Bacopaside V	BPS V
16.	Bacopaside VIII	BPS VIII
17.	Bacopaside XII	BPS XII
18.	Plantainoside B	PTS B
19.	Betulinic acid	BTA
20.	Cucurbitacin A	CCB A
21.	Cucurbitacin B	CCB B
22.	Cucurbitacin C	CCB C
23.	Cucurbitacin D	CCB D
24.	Cucurbitacin E	CCB E
25.	Stearic acid	STRA
26.	Rosavin	RSV
27.	3,4 Dimethoxycinnamic acid	3,4DMCA
28.	Ascorbic acid	ASBA
29.	Asiatic acid	ASTA
30.	Brahmic acid	BMA
31.	Wogonin	WG
32.	Oroxindin	OX
33.	Loliolide	LLD
34.	Stigmasterol	SGMS
35.	$\beta$ -sitosterol	$\beta$ -SS
36.	Ebelin lactone	EBL
37.	Stigmastanol	SGMSL
38.	Bacosterol	BCSt
39.	Bacosine	BCSn
40.	Heptacosane	HCS
41.	Octacosane	OCS

42.	Nonacosane	NCS
43.	Triacontane	TC
44.	Hentriacontane	HTA
45.	Dotriacontane	DOT
46.	Apigenin	AG
47.	Quercetin	QR
48.	Ursolic acid	USA
49.	Luteolin	LT
50.	Asiaticoside	ASTS
51.	Bacopaside VI	BPS VI
52.	Bacopaside VII	BPS VII

### Chemical Constituents

Since the prohibition of mixtures was unavoidable, we laid out a compensatory component to distinguish compounds with authoritative action in BM and dissected the variables that prompted their expulsion. For instance, the boundaries of Bacoside were: DL = 0.75; Caco2 = -0.85; OB = 40.12, and PPB = 75.5%. The Ames test was positive, just like the Carcino Mouse scores, while hERG restraint measures considered the mixtures generally safe (absolute score = 5 focuses). As indicated by these boundaries, bacoside was screened out in "Caco2" and "poisonousness expectations". Nonetheless, an exhaustive examination of the compound proposed it ought to hold determination as its higher "OB" esteem makes up for the low "Caco2" values noticed. As per the current writing, Bacoside showed no harmfulness and we consequently incorporated this compound as a functioning fixing. A sum of 11 mixtures were chosen through such advantageous components.

### Acquisition of NAFLD Targets

The consequences of looking through catchphrases including "non-alcoholic greasy liver infection", "non-alcoholic steatohepatitis", and "basic greasy liver" on GeneCards and MalaCards were downloaded and thoroughly dissected, leaving 84 pertinent NAFLD targets. The dynamic fixings were transferred onto the BM "SystemsDock" site, and potential BM targets in light of converse pharmacophore it were gotten to plan innovation. Through examination of the objective qualities, 17 tedious targets were acquired, that is to say, 17 potential objective qualities for the treatment of NAFLD by BM.

### Molecular Docking

Pymol programming and AutoDock Tools 1.5.6 were utilized to adjust proteins and dynamic fixings, separately, which were brought into AutoDock Tools 1.5.6 for sub-atomic docking. From the docking investigation, groups with the biggest number of adaptations and most elevated outright restricting energies were chosen, and greatest outright qualities for the limiting energy between the compound and the objective protein were acquired. Drug bank and writing look were utilized to recognize drugs with authoritative impacts on the objective proteins. Structures were downloaded utilizing sub-atomic docking approaches as

sure controls. Restricting energies were gotten as a screening edge and used to survey the limiting energy among mixtures and proteins. Dynamic fixings were distinguished that tight spot to the objective proteins.

### **Pathway Enrichment Analysis**

An aggregate of 17 objective qualities were coordinated and transferred to the DAVID data set. We chose "Identifier" as "OFFICIAL\_GENE\_SYMBOL", and "Homo sapiens" was chosen for "species" for KEGG pathway explanation. KEGG pathways were investigated, and those advanced in the objective qualities were considered significant administrative organizations for the BM treatment of NAFLD.

### **Constructing “Active Component--Target-Pathway” Networks**

Dynamic fixings, target qualities, and advancement pathways were acquainted into Cytoscape 3.6.1 programming with build dynamic fixing objective quality organizations and target quality improvement pathway organizations, individually. Dynamic parts and target qualities inside the improvement pathways were named as "hubs", and in the event that a relationship between two hubs was recognized, it was addressed as an "edge". Two gatherings of organizations were converged to get "Dynamic Component-Target-Pathway" organizations. In this organization structure, "hubs" with a high "Degree" esteem (compounds, targets, pathways) were considered to be of importance.

### **Preliminary Verification**

Information were checked in HepG2 cells. Adiponectin receptor 2 (ADIPOR2) was chosen as the objective and the adiponectin content of cell still up in the air by protein connected immunosorbent test (ELISA). We researched whether Bacoside-A, Bacoside-B, Nicotine, D-Mannitol, Brahmic Acid and Herpestine act through ADIPOQ/ADIPOR2. ADIPOR2 articulation and adenosine monophosphate-enacted protein kinase (AMPK) action downstream of the key middle person APPL1 were surveyed by Western Blot.

### **Cells**

HepG2 cells were purchased from NCCS, Pune. The cell source was ATCC hb-8065, generation P3.

### **Reagents**

Dulbecco's modified Eagle medium, fetal bovine serum, human adiponectin ELISA, human APPL1 antibody, human p-AMPK $\alpha$  antibody, human AMPK $\alpha$  antibody, and other Western blot reagents were purchased from Thermo Fisher Scientific Co., Ltd.

## Experimental assays


HepG2 cells in the logarithmic growth stage were seeded onto 96-well plates. Cells were either untreated (control) or treated Bacoside-A, Bacoside-B, Nicotine, D-Mannitol, Brahmic Acid and Herpestine, 24 hours postincubation, at 37°C in 5% carbon dioxide; the control groups were treated with serum-free culture media while the administration group was administered 0.1  $\mu\text{mol/mL}$  serum-free culture media for 30 minutes. ELISA was performed to assess the adiponectin levels of the supernatants.

For Western blot analysis, treated HepG2 cells were lysed and total protein content assessed via bicinchoninic acid assay. Samples were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred to polyvinylidene fluoride membranes. Membranes were blocked in 5% milk for 1 hour. Membranes were probed with antibodies against either p-AMPK $\alpha$  (1:1000), AMPK $\alpha$  (1:1000), APPL1 (1:1000), or glyceraldehyde 3-phosphate dehydrogenase (1:2000) overnight at 4°C. Membranes were washed in tris buffered saline-T and labeled with the appropriate horseradish peroxidase-conjugated secondary antibodies at room temperature for 2 hours. Proteins were visualized using the ECL system.

## Results

### Compound Information Retrieval

Fifty-two numbers of phytomolecules were used as a query in the PubChem database and the Molinspiration tool to retrieve the Canonical SMILIES and 3D structure of the compounds (Figure 1). This collected information was used for further analyses.



### Active Compound Screening

As per both screening and compensatory components, 11 mixtures were recognized. A large portion of the 11 mixtures were flavonoids and their glycosides, trailed by saponins and alkaloids. DL and ADME upsides of the mixtures were evaluated for drug-like properties and recorded. The after effects of these examinations are displayed in Table 2B.

Table 2B: Active Compound Screening

Components	DL	Caco2	OB (%)	PPB (%)
Nicotine	0.24	0.56	48.6	46.5
D-Mannitol	0.24	0.67	35.0	37.1
Bacoside A	0.23	0.79	30.7	76.1
Bacopasaponin A	0.21	0.63	33.5	67.2
Bacopasaponin B	0.86	1.21	30.7	58.2
Bacopasaponin C	0.75	1.32	36.9	55.7
Bacopasaponin D	0.24	0.58	34.0	36.7
Bacopasaponin E	0.28	0.55	36.2	40.1
Bacopasaponin F	0.33	0.43	38.1	42.4
Bacopasaponin G	0.42	0.65	24.5	35.6
Bacopaside I	0.21	0.63	33.5	67.2

### Screening of Potential Targets

An aggregate of 84 NAFLD-related qualities were gotten from Malacards and Gene Cards data sets and contrasted and the aftereffects of opposite pharmacophore coordinating. A sum of 17 potential NAFLD focuses for BM treatment were gotten. These objectives were communicated as their quality images, as displayed in Table 3.

**Table 3.** Screening of Potential Targets.

Uniprot ID	Protein	Gene names
Q13085	Acetyl-CoA carboxylase 1	ACACA
Q15848	Adiponectin	ADIPOQ
Q96A54	Adiponectin receptor protein 1	ADIPOR1
Q86V24	Adiponectin receptor protein 2	ADIPOR2
P05181	Cytochrome P450 2E1	CYP2E1
P07148	Fatty acid-binding protein, liver	FABP1
P49327	Fatty acid synthase	FASN
P19440	Glutathione hydrolase 1 proenzyme	GGT1
P06213	Insulin receptor	INSR
P48357	Leptin receptor	LEPR
P45983	Mitogen-activated protein kinase 8	MAPK8
Q07869	Peroxisome proliferator-activated receptor alpha	PPARA
P37231	Peroxisome proliferator-activated receptor gamma	PPARG
P02753	Retinol-binding protein 4	RBP4
O00767	Stearoyl-CoA Desaturase	SCD
P36956	Sterol regulatory element-binding protein 1	SREBF1
P01375	Tumor necrosis factor	TNF

### Molecular Docking


The mol2 arrangement of BM dynamic fixings was downloaded from the TCMSP data set and put away after transformation into the pdbqt design in groups. Protein X-beam diffraction structures were downloaded from the PDB information base and saved in the PDB design. AutoDock Tools were utilized to deligand, desolvent, and hydrogenate the acquired protein structures, which were saved in the pdbdt design. Target designs and dynamic fixings were brought into AutoDock Tools 1.5.6 for sub-atomic docking. Gridbox boundaries allude to the normal directions got while eliminating protein ligands. This was performed multiple times for every protein and groups with the biggest adaptations and outright restricting energies were chosen, involving the limiting energy between the compound and the objective protein. Through writing investigation, joined with flow research areas of interest, positive controls of every protein target were chosen, and sub-atomic mooring was performed under indistinguishable circumstances. Restricting energies were acquired and utilized as a limit for compound screening. For dubious positive control medicates, the first 30% (the initial 32 mixtures) were chosen by the limiting energies of each compound/protein. Boundaries of the positive medications and lattice confines are shown Table 4.

**Table 4.** Positive Drugs and Gridbox Parameters for Each Target Protein.

Gene names	Positive control drug	Gridbox parameter
ACACA	ND630	-23.44/-37.45/19.58
ADIPOQ	AdipoRon	1.51/-23.20/4.17
ADIPOR1	AdipoRon	19.43/35.75/-6.40
ADIPOR2	AdipoRon	17.95/23.12/29.91
CYP2E1	DADS	20.93/13.13/21.87
FABP1	BMS309403	28.04/-3.14/-37.46
FASN	Orlistat	21.72/29.729/22.93
GGT1	CHEMBL3912207	-24.186/-22.53/-9.53
INSR	-	-23.44/32.69/10.43
LEPR	-	57.41/32.47/2.76
MAPK8	SB239063	4.81/32.56/20.55
PPARA	Fenofibrate	31.70/30.18/29.90
PPARG	Pioglitazone	8.90/23.90/18.24
RBP4	Fenretinide	18.74/48.53/-35.80
SCD	-	15.0634/76.33/48.99
SREBF1	Fatostatin	44.93/32.93/155.39
TNF	Etanercept	21.84/45.34/42.92


### Target Path Annotations

All potential objective qualities were coordinated and transferred onto the DAVID data set for KEGG pathway explanation. The limit esteem was set to  $P \leq 0.05$  and either higher pathway or quality capacities were dissected. Graphpad Prism 6 was utilized to plot the initial ten things, with results displayed in Figure 2. KEGG pathway explanation showed that every one of the 17 objective qualities were associated with pathway advancement (100 percent), including 12 pathways, 11 of which essentially related with the objective qualities ( $P < 0.05$ ). The main pathways included AMPK flagging (11, 64.7%), NAFLD (10, 58.8%), adipocytokine flagging (7, 41.2%), PPAR flagging (6, 35.3%), insulin obstruction (5, 29.4%), and type II diabetes mellitus (5, 29.4%). Further similar examination of the 10 KEGG pathways with the most grounded connection uncovered that among the 17 objective qualities, the related qualities included MAPK8, TNF, INSR, PPARA, PPARG, ACACACA, ADIPOQ, FASN, SREBF1, and ADIPOR1. These qualities are the logical focuses of BM during NAFLD treatment.



### Construction of “Active Component-Target Gene-Enrichment Pathway” Networks


The 4 pathways with the biggest number of target qualities were acquired from the pathways fundamentally associating with target qualities (Figure 3). These pathways, 17 objective qualities, and 108 parts were utilized to build an organization of dynamic fixing objective quality advancement pathways utilizing Cytoscape programming. As indicated by the information, compounds with a degree >10 were chosen for investigation. Among them, the quantity of flavonoids was the most noteworthy, trailed by coumarins, while the quantity of alkaloids was generally low.



### Enzyme-Linked Immunosorbent Assay


ELISA was performed to evaluate the substance of adiponectin in the supernatants of HepG2 cells. The 5 medication bunches decided are displayed in

Figure 5. Bacoside-A was found to upgrade the outflow of adiponectin in HepG2 cells, showing tremendous contrasts contrasted and the benchmark group. No massive impacts on adiponectin articulation were seen in HepG2 cells.



### Western Blot Analysis

Following 30 minutes of brooding, the statement of AMPK $\alpha$  in HepG2 cells didn't contrast between Bacoside-A, Bacoside-B, Nicotine, D-Mannitol and Herpestine. The declaration of p-AMPK $\alpha$  fundamentally expanded in Bacoside-B, herpestine, Brahmic corrosive, and Bacoside-A gatherings, without any progressions altogether AMPK $\alpha$  levels, affirming AMPK $\alpha$  actuation. Bacoside B, Herpestin, and Brahmic Acid altogether expanded the statement of APPL1 following 30 minutes of treatment, proposing that they follow up on ADIPOR2. These outcomes are summed up in Figure 5. Be that as it may, the instrument of Bacoside-A might contrast, as it is known to upgrade adiponectin articulation, an activator of ADIPOR2. The component of activity of this compound requires further explanation in later examinations



### Discussion

NAFLD is brought about by liver pressure that is firmly identified with glycolipid digestion problems and is portrayed by hepatocyte steatosis and liver fatty substance collection. Its clinical appearances incorporate NAFL, NASH, and non-heavy drinker cirrhosis. The occurrence of NAFLD in everyone is pretty much as

high as 20%- 33%. With improved human expectations for everyday comforts, NAFLD is expanding consistently. It has been shown that roughly 10%-25% of NAFLD patients dynamically create NASH; 40% of NASH patients create liver fibrosis, 10%-15% of NASH patients create cirrhosis, and 9%-26% of NASH-related cirrhosis patients bite the dust inside 4-10 years of follow-up. NAFLD consequently represents a genuine danger to human wellbeing. Compelling safeguard what's more, remedial NAFLD medicines can diminish the rate of cirrhosis, liver malignant growth, and diminish atherosclerotic cardiovascular and cerebrovascular sicknesses.

ADIPOR2 is communicated in liver cells and plays a significant part in glycolipid digestion. At the point when actuated, the receptor initiates APPL1 to straightforwardly or by implication tweak cell flagging pathways (counting AMPK). ADIPOR2 action can be surveyed through APPL1 articulation. The actuation of this pathway is additionally subject to AMPK flagging. AMPK comprises of 3 subunits:  $\alpha$ ,  $\beta$ , and  $\gamma$ 28,29; Thr172 addresses the dynamic site of the  $\alpha$ -reactant subunit and the degrees of p-AMPK $\alpha$  straightforwardly mirror the degrees of AMPK actuation. It is conjectured that the mixtures impact lipid digestion in HepG2 cells through the ADIPOR2/APPL1/AMPK hub to reduce the impacts of NAFLD.<sup>30</sup> Specifically, Brahmic Acid, Bacoside - B and D-Mannitol altogether expanded the outflow of APPL1 and p-AMPK $\alpha$  in HepG2 cells, recommending that they follow up on ADIPOR2. These information confirmed the organization pharmacology information. Of note, the outflow of APPL1 didn't change upon Bacoside-A treatment, in spite of the actuation of p-AMPK $\alpha$ . Accordingly, Bacoside-A may not actuate AMPK through the ADIPOR2 receptor and its particular systems require further examination.

In outline, we have contemplated the pharmacodynamics and components of BM activity during the treatment of NAFLD through network pharmacology. Through a progression of estimations, we screened 9 possibly dynamic substances in BM, 10 potential targets identified with NAFLD, and 4 pathways prone to apply their pharmacodynamic impacts. It was affirmed that Bacoside-B, D-Mannitol and Brahmic Acid follow up on their anticipated targets and that ADIPOR2 enacts AMPK motioning to control lipid digestion. These information feature the dependability of the network pharmacology information and backing the treatment of NAFLD utilizing *Bacopa monniera*.

## References

- Abenavoli, L., Milic, N., Di Renzo, L., Preveden, T., Medic-Stojanoska, M., De Lorenzo, A., (2016) Metabolic aspects of adult patients with nonalcoholic fatty liver disease, *World J. Gastroenterol.* 22(31): 7006–7016.
- Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., Angulo, P., (2005) The natural history of nonalcoholic fatty liver disease: a populationbased cohort study, *Gastroenterology* 129(1):113–121.
- Beaton, M.D., (2012) Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, *Can. J. Gastroenterol.* 26(6):353–357.
- Bhala, N., Younes, R., Bugianesi, E., (2013) Epidemiology and natural history of patients with NAFLD, *Curr. Pharm. Des.* 19(29):5169–5176.

- Chakravarty, A.K., Garai, S., Masuda, K., Nakane, T., Kawahara, N., (2003) Bacopasides III V: Three new Triterpenoid Glycosides from *Bacopa monnieiri*. Chem. Pharma. Bull., 51:215-217.
- Chakravarty, A.K., Sarkar, T., Masuda, K., Shiojima, K., Nakane, T., Kawahara, N. *et al.*, (2001) Bacopaside I and II: Two Pseudojubilogenin Glycosides from *Bacopa monnieiri*. Phytochemistry, 58:553-556.
- Corrado, R.L., Torres, D.M., Harrison, S.A., (2014) Review of treatment options for nonalcoholic fatty liver disease, Med. Clin. North Am. 98(1):55-72.
- Deepak, M., Sangli, G.K., Arun, P.C., Amit, A., (2005) Quantitative determination of the major saponin mixture Bacoside A in *Bacopa monniera* by HPLC. Phytochem Anal, 16:24.
- Diehl, A.M., Day, C., (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis, N. Engl. J. Med. 377(21):2063-2072.
- Garai, S., Mahato, S.B., Ohtani, K., Yamasaki, K. *et al.*, 1996. Bacosaponin D- A Pseudojubilogenin Glycoside from *Bacopa monnieiri*. Phytochemistry, 43, 447-449.
- Garai, S., Mahato, S.B., Ohtani, K., Yamasaki, K., (1996) Dammarane- Type Triterpenoid Saponins from *Bacopa monnieiri*. Phytochemistry, 42:815- 820.
- Henaoui-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W.Z., Strowig, T., Thaïs, C.A., Kau, A.L., Eisenbarth, S.C., Jurczak, M.J., Camporez, J.P., Shulman, G.I., Gordon, J.I., Hoffman, H.M., Flavell, R.A., (2012) Inflammation-mediated dysbiosis regulates progression of NAFLD and obesity, Nature 482(7384):179-185.
- Hui, J.M., Kench, J.G., Chitturi, S., Sud, A., Farrell, G.C., Byth, K., Hall, P., Khan, M., George, J., (2003) Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C, Hepatology 38(2):420-427.
- Kopce, K.L., Burns, D., (2011) Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy, Nutr. Clin. Pract. 26(5):565-576.
- Kwon, Y.M., Oh, S.W., Hwang, S.S., Lee, C., Kwon, H., Chung, G.E., (2012) Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults, Am. J. Gastroenterol. 107(12):1852-1858.
- L. European Association for the Study of the, D. European Association for the Study of, O. European Association for the Study of, (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, Diabetologia 59(6):1121-1140.
- Le, T.A., Loomba, R., (2012) Management of non-alcoholic fatty liver disease and steatohepatitis, J. Clin. Exp. Hepatol. 2(2):156-173.
- Mahato, S.B., Garai, S., Chakravarty, A.K., (2000) Bacopasaponins E and F: Two Jubilogenin Bisdesmosides from *Bacopa monnieiri*. Phytochemistry, 53:711-714.
- Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology 116(6):1413-1419.
- Rastogi, R.M., Mehrotra, B.N., (1998) Compendium Indian Medicinal Plants. Vol V: 1990-1994. CDRI, Lucknow and Publication and Information Directorate, New Delhi, pp, 120.
- Rastogi, R.M., Mehrotra, B.N., (1991) Compendium Indian Medicinal Plants. Vol. I: 1960-1969. CDRI, Lucknow and Publication and Information Directorate, New Delhi, pp, 53-54.

- Rastogi, R.M., Mehrotra, B.N., (1993) Compendium Indian Medicinal Plants. Vol. II: 1970 1979. CDRI, Loknow and Publication and Information Directorate, New Delhi, pp, 91.
- Rastogi, R.M., Mehrotra, B.N., (1995) Compendium Indian Medicinal Plants. Vol. IV: 1985 1989. CDRI, Loknow and Publication and Information Directorate, New Delhi, pp, 96.
- Ratziu, V., Bonyhay, L., Di Martino, V., Charlotte, F., Cavallaro, L., Sayegh-Tainturier, M.H., Giral, P., Grimaldi, A., Opolon, P., Poynard, T., (2002) Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis, *Hepatology* 35(6):1485-1493.
- Sairam, K., Rao, C.V., Babu, M.D., Goel, R.K., (2001) Prophylactic and curative effects of *Bacopa monniera* in gastric ulcer models. *Phytomed*, 8:423-30.
- Sattar, N., Forrest, E., Preiss, D., (2014) Non-alcoholic fatty liver disease, *BMJ* 349:g4596.
- Sayiner, M., Koenig, A., Henry, L., Younossi, Z.M., (2016) Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world, *Clin. Liver Dis.* 20 (2):205–214.
- Shobana, C., Sumathi, T., (2013) Studies on behavioral, biochemical, immunohistochemical and quantification of dopamine and its metabolites in the striatum of 6-hydroxy dopamine induced Parkinsonism in rats - Attenuation by Bacoside-A, a major phytoconstituent of *Bacopa monniera*. *International Journal of Applied Biology and Pharmaceutical Technology*, 4(4):120-142.
- Starley, B.Q., Calcagno, C.J., Harrison, S.A., (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection, *Hepatology* 51(5):1820–1832.
- The Wealth of India, (1988) A Dictionary of Indian Raw materials and Industrial products; Raw materials Publications and Information Directorate, 2: 2-3.
- Warrier, P.K., Nambiar, V.P.K., Ramankutty, C., (1994) Indian Medicinal Plants: A Compendium of 500 species. Orient Longman, 2:235.
- Xu, J.Y., Zhang, L., Li, Z.P., Ji, G., (2015) Natural products on nonalcoholic fatty liver disease, *Curr. Drug Targets* 16(12):1347–1355.